

COMMUNICATING THE FINANCIAL CONSEQUENCES OF CANCER CARE

Yousuf Zafar, MD, MHS, FASCO
Associate Professor of Medicine, Public Policy, & Population Health Science
Chief Quality & Innovation Officer
Duke Cancer Institute



Why?

1. Treatment is expensive
2. Cost-sharing is increasing
3. ?

Why?

1. Treatment is expensive
2. Cost-sharing is increasing
3. **Me**

Diet

Deductibles

Travel

Lost income

Co-pays

Child care

Coinsurance

Legal
services

Supplies

Direct costs

Deductibles

Co-pays

Coinsurance

Indirect costs

Child care

Travel

Supplies

Lost income

Legal
services

Diet

Cost-related
material
hardship

Objective
out-of-pocket
costs

Cost-related
psychological
hardship

Subjective
concern
about costs



Goals of care

Risk of heart
attack with
bevacizumab

2%


Risk of
material
hardship

25%

Risk of
psychological
hardship

34%

Prevent
fatigue



Assess
fatigue



Reduce
fatigue

Prevent
financial
toxicity



```
graph LR; A[Prevent financial toxicity] --> B[Assess financial toxicity]; B --> C[Reduce financial toxicity];
```

Assess
financial
toxicity

Reduce
financial
toxicity

